Want to join the conversation?
In 2Q16, $REGN reported positive data from three Phase III studies of dupilumab, a drug for eczema, an itchy skin condition. The company has submitted Biologics License Application for dupilumab in the U.S. $REGN expects FDA action for Sarilumab, a drug for treating rheumatoid arthritis, by October 30.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.